These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19683985)

  • 1. Immunoreactivity for alpha-smooth muscle actin characterizes a potentially aggressive subgroup of little basal cell carcinomas.
    Pilloni L; Bianco P; Manieli C; Senes G; Coni P; Atzori L; Aste N; Faa G
    Eur J Histochem; 2009; 53(2):e14. PubMed ID: 19683985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microcystic adnexal carcinoma: an immunohistochemical study including markers of proliferation and apoptosis.
    Smith KJ; Williams J; Corbett D; Skelton H
    Am J Surg Pathol; 2001 Apr; 25(4):464-71. PubMed ID: 11257620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of basal cell carcinoma and trichepithelioma using Bcl-2, Ki67, PCNA and P53.
    Abdelsayed RA; Guijarro-Rojas M; Ibrahim NA; Sangueza OP
    J Cutan Pathol; 2000 Apr; 27(4):169-75. PubMed ID: 10774937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical nuclear staining for p53, PCNA, Ki-67 and bcl-2 in different histologic variants of basal cell carcinoma.
    Mateoiu C; Pirici A; Bogdan F
    Rom J Morphol Embryol; 2011; 52(1 Suppl):315-9. PubMed ID: 21424069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical expression of p53, Ki67, α-SMA, CD44 and CD31 in different histological subtypes of basal cell carcinoma.
    Cojocaru A; Bîrjovanu C; Ciurea AM; Niculescu D; Orzan OA; Ion A; Alexandru DO; Pirici I; Vîlcea EJ; Marinescu EA; Ciurea ME
    Rom J Morphol Embryol; 2022; 63(2):383-393. PubMed ID: 36374143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of p53, D2-40 and α-smooth muscle actin in different histological subtypes of facial basal cell carcinoma.
    Mercut R; Ciurea ME; Mărgăritescu C; Popescu SM; Crăitoiu MM; Cotoi OS; Voinescu DC
    Rom J Morphol Embryol; 2014; 55(2):263-72. PubMed ID: 24969973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis.
    Vidal D; Matías-Guiu X; Alomar A
    Br J Dermatol; 2004 Sep; 151(3):656-62. PubMed ID: 15377354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma.
    Adegboyega PA; Rodriguez S; McLarty J
    Hum Pathol; 2010 Aug; 41(8):1128-37. PubMed ID: 20381122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-2-related proteins, alpha-smooth muscle actin and amyloid deposits in aggressive and non-aggressive basal cell carcinomas.
    Bozdogan O; Erkek E; Atasoy P; Koçak M; Birol A; Caydere M
    Acta Derm Venereol; 2002; 82(6):423-7. PubMed ID: 12575847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A correlation of alpha-smooth muscle actin and invasion in micronodular basal cell carcinoma.
    Christian MM; Moy RL; Wagner RF; Yen-Moore A
    Dermatol Surg; 2001 May; 27(5):441-5. PubMed ID: 11359490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
    Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
    Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comparative Study of CD56 and Smooth Muscle Actin Expression in Basal and Squamous Cell Carcinomas.
    Yirmibes S; Balaban Adim S
    Am J Dermatopathol; 2023 Dec; 45(12):816-819. PubMed ID: 37982465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcl-2 protein expression in aggressive and non-aggressive basal cell carcinomas.
    Ramdial PK; Madaree A; Reddy R; Chetty R
    J Cutan Pathol; 2000 Jul; 27(6):283-91. PubMed ID: 10885404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates.
    Nakopoulou L; Vourlakou C; Zervas A; Tzonou A; Gakiopoulou H; Dimopoulos MA
    Hum Pathol; 1998 Feb; 29(2):146-54. PubMed ID: 9490274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma.
    Barrett TL; Smith KJ; Hodge JJ; Butler R; Hall FW; Skelton HG
    J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):430-7. PubMed ID: 9308559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
    Ionescu DN; Arida M; Jukic DM
    Arch Pathol Lab Med; 2006 Jan; 130(1):45-51. PubMed ID: 16390237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin expression in purely nodular versus nodular-infiltrative basal cell carcinoma.
    Law AM; Oliveri CV; Pacheco-Quinto X; Horenstein MG
    J Cutan Pathol; 2003 Apr; 30(4):232-6. PubMed ID: 12680952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck.
    Staibano S; Lo Muzio L; Pannone G; Scalvenzi M; Salvatore G; Errico ME; Fanali S; De Rosa G; Piattelli A
    Anticancer Res; 2001; 21(6A):3757-64. PubMed ID: 11911244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD56 and smooth muscle actin immunoreactivity in basal cell carcinomas: Are they indicators of differentiation or do they hold a diagnostic use?
    Yirmibeş S; Adım ŞB; Saraydaroğlu Ö
    J Cutan Pathol; 2023 Jan; 50(1):56-61. PubMed ID: 36054407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunomorphological features of cutaneous basal-cell carcinoma].
    Chuprov IN
    Vopr Onkol; 2008; 54(6):715-9. PubMed ID: 19241845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.